Bristol-Myers Squibb Company (BMY) as of 05/19/2023

Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that specializes in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. The company operates in the healthcare sector, specifically in the field of drug manufacturing.

Some of the key products offered by Bristol-Myers Squibb include Eliquis for reducing the risk of stroke and systemic embolism, Opdivo for anti-cancer indications, Pomalyst/Imnovid for multiple myeloma, and Orencia for rheumatoid arthritis and psoriatic arthritis, among others. The company's product portfolio covers a wide range of therapeutic areas such as hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.

In terms of financials, Bristol-Myers Squibb has a market capitalization of $138.39 billion. The company has a trailing price-to-earnings (P/E) ratio of 19.21, which indicates that the stock is trading at a relatively moderate valuation compared to its earnings. The forward P/E ratio is 8.76, suggesting a lower valuation expectation for future earnings.

The stock has a dividend yield of 3.43%, with a trailing annual dividend rate of $2.22. The payout ratio is 0.6472, indicating that the company distributes approximately 64.72% of its earnings as dividends. It's worth noting that the dividend yield is relatively low compared to the five-year average of 3.01%. This suggests that the stock may not be primarily attractive for income-seeking investors.

In terms of risk factors, Bristol-Myers Squibb has an overall risk rating of 1, which indicates a relatively low level of risk. The company's governance, compensation, and shareholder rights risks are also relatively low, while the board risk is moderate. It's important to consider these risk factors in the context of your investment strategy and risk tolerance.

From a technical perspective, the stock's price has been fluctuating between a 52-week low of $65.18 and a 52-week high of $81.44. The current price is $65.875, which is close to the lower end of this range. The stock's performance should be analyzed in conjunction with market trends, industry dynamics, and the company's fundamental outlook.

Analysts' consensus opinion on the stock is currently a "buy," with a target mean price of $73.7. This suggests that analysts expect the stock to appreciate from its current price level.

In summary, Bristol-Myers Squibb is a leading biopharmaceutical company with a diverse product portfolio and a strong presence in various therapeutic areas. While the stock is currently trading at a relatively moderate valuation and offers a dividend, its low dividend yield may not be the primary attraction for income-seeking investors. Investors should consider the company's financial performance, industry trends, and risk factors when making investment decisions.

Let's analyze the financial measures of Bristol-Myers Squibb (BMY):

1. EPS (Earnings Per Share): The EPS for BMY is $3.43. EPS represents the portion of a company's profit allocated to each outstanding share of common stock. It is an important measure of a company's profitability.

2. Trailing Price to Earnings Ratio: The trailing P/E ratio for BMY is 19.2055. The P/E ratio is a valuation metric that compares the current market price of a stock to its earnings per share. A higher P/E ratio suggests that investors are willing to pay a higher price for each dollar of earnings.

3. Price to Book Ratio: The price-to-book ratio for BMY is 4.34704. This ratio compares the market price of a company's stock to its book value per share. It indicates how much investors are willing to pay for each dollar of net assets.

4. Dividend Yield (%): BMY has a dividend yield of 3.43%. Dividend yield represents the annual dividend payment as a percentage of the stock's current price. It indicates the return an investor can expect to receive from dividends.

5. Return on Equity (%): The return on equity for BMY is 23.072%. ROE measures the profitability of a company in relation to shareholders' equity. It shows how effectively a company is utilizing shareholder investments to generate profits.

6. Debt to Equity Ratio: BMY has a debt to equity ratio of 123.518. This ratio indicates the proportion of debt financing relative to shareholders' equity. A higher debt to equity ratio suggests a higher level of financial leverage.

7. Free Cash Flow: BMY generated $12,602.4 million in free cash flow. Free cash flow measures the cash a company has left after deducting capital expenditures. It represents the cash available for reinvestment, debt repayment, and distribution to shareholders.

8. Market Capitalization: The market capitalization of BMY is $138,394 million. Market capitalization is the total value of a company's outstanding shares in the stock market. It is calculated by multiplying the current stock price by the number of shares outstanding.

9. Revenue Growth (%): BMY experienced a revenue growth rate of -2.7%. This measure compares the change in a company's revenue over a specific period, indicating the company's ability to increase sales.

10. Operating Margin (%): The operating margin for BMY is 20.797%. This margin represents the proportion of revenue left after deducting operating expenses. It indicates the profitability of a company's core operations.

11. Forward Price to Earnings Ratio: The forward P/E ratio for BMY is 8.75997. This ratio uses estimated future earnings to calculate the P/E ratio. It provides insight into the market's expectations for the company's future performance.

Overall, these financial measures provide an overview of BMY's profitability, valuation, leverage, cash flow, and market performance. It is important to consider these measures along with other factors and conduct a comprehensive analysis before making any investment decisions.

                  Financial Measure  Percentile Stock
0                           EPS         33.333333
1                     P/E Ratio         41.666667
2                     P/B Ratio         50.549451
3            Dividend Yield (%)         66.666667
4              Return On Equity         56.818182
5                Debt to Equity         57.831325
6   Free cash Flow (in million)         80.000000
7       Market Cap (in million)         50.000000
8                Revenue Growth         25.773196
9              Operating Margin         50.515464
10                        Total        513.154284

The percentiles of Bristol-Myers Squibb's (BMY) financial measures compared to the S&P 100 stocks are as follows:

1. EPS: BMY's EPS percentile is 33.33%, indicating that its earnings per share is higher than approximately one-third of the S&P 100 stocks.

2. P/E Ratio: BMY's trailing price-to-earnings ratio percentile is 41.67%, suggesting that its valuation based on earnings is higher than approximately 41.67% of the S&P 100 stocks.

3. P/B Ratio: BMY's price-to-book ratio percentile is 50.55%, indicating that its valuation based on book value is higher than approximately half of the S&P 100 stocks.

4. Dividend Yield (%): BMY's dividend yield percentile is 66.67%, suggesting that its dividend yield is higher than approximately two-thirds of the S&P 100 stocks. 

5. Return On Equity: BMY's return on equity percentile is 56.82%, indicating that its profitability measured by return on equity is higher than approximately 56.82% of the S&P 100 stocks.

6. Debt to Equity Ratio: BMY's debt-to-equity ratio percentile is 57.83%, suggesting that its level of debt relative to equity is higher than approximately 57.83% of the S&P 100 stocks.

7. Free Cash Flow (in million dollars): BMY's free cash flow percentile is 80%, indicating that its ability to generate cash flow is higher than approximately 80% of the S&P 100 stocks.

8. Market Capitalization (in million dollars): BMY's market capitalization percentile is 50%, suggesting that its market value is higher than approximately half of the S&P 100 stocks.

9. Revenue Growth (%): BMY's revenue growth percentile is 25.77%, indicating that its revenue growth rate is higher than approximately 25.77% of the S&P 100 stocks.

10. Operating Margin (%): BMY's operating margin percentile is 50.52%, suggesting that its operating profitability is higher than approximately half of the S&P 100 stocks.

Overall, based on these percentiles, BMY's financial measures generally fall within the range of other S&P 100 stocks, with some measures performing better than the median and others performing worse. It is important to note that these percentiles provide a relative comparison to the S&P 100 stocks and should be considered in conjunction with other factors when evaluating BMY's financial performance.